Identification of PML/RARα rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients

[1]  Benz,et al.  Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia , 2000, British journal of haematology.

[2]  D. Grimwade,et al.  Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. , 1999, Blood.

[3]  C. Preudhomme,et al.  Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases , 1999, Leukemia.

[4]  F. Mandelli,et al.  Acute promyelocytic leukemia: a curable disease , 1998, Leukemia.

[5]  I. Dobo,et al.  Use of collagen for standardization of PBSC graft quality evaluation: a multicenter comparative analysis of commercial collagen-based and methylcellulose-based colony-forming unit (CFU) assay kits. , 1998, Journal of hematotherapy.

[6]  D. Le Tessier,et al.  Fluorescence in situ hybridization on methylcellulose cultured hematopoietic stem cells from myelodysplastic syndromes. , 1998, Cancer genetics and cytogenetics.

[7]  P. Freemont,et al.  Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. , 1997, Blood.

[8]  A. List,et al.  Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. , 1997, Blood.

[9]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[10]  D. Grimwade,et al.  Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial , 1996, British journal of haematology.

[11]  P. Morel,et al.  Cytogenetics of myelodysplastic syndromes. , 1996, Seminars in hematology.

[12]  K. Kojima,et al.  Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. , 1996, Leukemia.

[13]  S. Langabeer,et al.  Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. , 1996, Leukemia.

[14]  G. Avvisati,et al.  Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission , 1995, British journal of haematology.

[15]  I. Dobo,et al.  Collagen matrix: an attractive alternative to agar and methylcellulose for the culture of hematopoietic progenitors in autologous transplantation products. , 1995, Journal of hematotherapy.

[16]  G. Dewald,et al.  Efficacy of fluorescence in situ hybridization for detecting PML/RARA gene fusion in treated and untreated acute promyelocytic leukemia. , 1994, Mayo Clinic proceedings.

[17]  E. Dmitrovsky,et al.  Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Rowley,et al.  Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. , 1984, The American journal of medicine.

[19]  M. Lanotte.  Terminal differentiation of hemopoietic cell clones cultured in tridimensional collagen matrix: in situ cell morphology and enzyme histochemistry analysis , 1984, Biology of the cell.

[20]  A. Sandberg,et al.  Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocations in CML , 1980, Cancer.

[21]  K. McPherson,et al.  MORTALITY IN ORAL CONTRACEPTIVE USERS , 1981, The Lancet.

[22]  J. Rowley,et al.  15/17 TRANSLOCATION, A CONSISTENT CHROMOSOMAL CHANGE IN ACUTE PROMYELOCYTIC LEUKAEMIA , 1977, The Lancet.